Medpace Holdings, Inc.(MEDP)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Medpace Holdings, Inc. (MEDP) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MEDP at 76.2/100 on a 32-signal composite quality model, placing it at rank #86 of 2,960 stocks — the top 5% of the AI-ranked universe. MEDP scores in the top quartile across balance sheet strength (98.0), institutional flow (79.1), free cash flow (79.0). Shareholder dilution risk is elevated at 48.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Medpace Holdings, Inc. reports quarterly revenue of $707.3M, net income of $121.4M, an operating margin of 20.8%. Top institutional holders of MEDP by reported 13-F value include BlackRock, PRICE T ROWE ASSOCIATES, AQR CAPITAL MANAGEMENT, based on the most recent SEC filings. MEDP trades on the Nasdaq exchange and files with the SEC under CIK 1668397. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MEDP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Medpace Holdings, Inc. directly from SEC EDGAR.
AI Quality Score
76.2/100
AI Rank
#86
Revenue
$707.3M
Net Income
$121.4M
Free Cash Flow
$138.1M
Operating Margin
20.8%
MEDP key financials by period
Medpace Holdings, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$2.5B
$451.1M
21.1%
FY 2024
10-K
$2.1B
$404.4M
21.2%
FY 2023
10-K
$1.9B
$282.8M
17.9%
FY 2022
10-K
$1.5B
$245.4M
19.1%
FY 2021
10-K
$1.1B
$181.8M
17.4%
FY 2020
10-K
$925.9M
$145.4M
18.0%
Institutions holding MEDP
Institutional investors reporting a position in Medpace Holdings, Inc. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-07-23 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revenue rose 17.2% to $707.3 million on Metabolic, Oncology, CNS and AVAI growth, with net income up to $121.4 million, while backlog grew only 4.9% to $3,014.2 million.
Biggest Revenue Drivers
Metabolic$219.1M
Filing cites growth within the Metabolic therapeutic area versus the prior-year period.
Oncology$209.4M
Filing cites growth within the Oncology therapeutic area versus the prior-year period.
Biggest Revenue Drivers
Total revenue: $707.3M+17.2% YoY
Metabolic$219.1M
Filing cites growth within the Metabolic therapeutic area versus the prior-year period.
Oncology$209.4M
Filing cites growth within the Oncology therapeutic area versus the prior-year period.
Other$98.3M
Central Nervous System$82.9M
Filing cites growth within the Central Nervous System therapeutic area versus the prior-year period.
Can fluctuate significantly period to period based on the timing of program initiation and closeout.
Direct service costs, excluding D&A$202.6M+9.0% YoY
Higher personnel costs to support growth in service activities, up $15.1 million.
Selling, general and administrative$48.1M+3.1% YoY
Primarily higher personnel costs of $0.8 million to support growth in service activities.
Depreciation$6.6M-3.3% YoY
Remained relatively consistent with the prior-year quarter.
Margins: Total direct costs rose 19.5% versus 17.2% revenue growth, driven mainly by reimbursed out-of-pocket expenses; income from operations still increased to $146.8 million from $126.3 million.
Watch Items from the Filing
Securities class action (filed April 6, 2026) and a June 22, 2026 derivative suit allege misleading statements on book-to-bill; no liability recognized as loss is not estimable.
Backlog grew just 4.9% to $3,014.2 million versus 17.2% revenue growth; remaining performance obligations fell to $3.5 billion from $3.6 billion.
Related-party revenue fell to $4.7 million from $16.9 million YoY, with CinRx contributing $3.5 million versus $15.1 million.
Repurchased 705,616 shares for $294.7 million in the quarter at an average $417.70; $527.0 million authorization remains, funded from $502.7 million cash and no debt.
Effective tax rate fell to 20.0% from 27.5%, aided by Foreign Derived Deduction Eligible Income and uncertain tax position benefits — a non-operating earnings tailwind.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
